Register for updates

 
 

Medicine & Health
RSS Feed
TAU Scientists Print First 3D Heart Using Patient’s Own Cells and Materials
Monday, April 15, 2019 9:00:00 AM

Engineered heart completely matches the immunological, cellular, biochemical and anatomical properties of the patient

In a major medical breakthrough, Tel Aviv University researchers have "printed" the world's first 3D vascularised engineered heart using a patient's own cells and biological materials. Their findings were published on April 15 in a study in Advanced Science.

Until now, scientists in regenerative medicine — a field positioned at the crossroads of biology and technology — have been successful in printing only simple tissues without blood vessels.

"This is the first time anyone anywhere has successfully engineered and printed an entire heart replete with cells, blood vessels, ventricles and chambers," says Prof. Tal Dvir of TAU's School of Molecular Cell Biology and Biotechnology, Department of Materials Science and Engineering, Center for Nanoscience and Nanotechnology and Sagol Center for Regenerative Biotechnology, who led the research for the study.

Heart disease is the leading cause of death among both men and women in the United States. Heart transplantation is currently the only treatment available to patients with end-stage heart failure. Given the dire shortage of heart donors, the need to develop new approaches to regenerate the diseased heart is urgent.

"This heart is made from human cells and patient-specific biological materials. In our process these materials serve as the bioinks, substances made of sugars and proteins that can be used for 3D printing of complex tissue models," Prof. Dvir says. "People have managed to 3D-print the structure of a heart in the past, but not with cells or with blood vessels. Our results demonstrate the potential of our approach for engineering personalized tissue and organ replacement in the future."

Research for the study was conducted jointly by Prof. Dvir, Dr. Assaf Shapira of TAU's Faculty of Life Sciences and Nadav Moor, a doctoral student in Prof. Dvir's lab.

"At this stage, our 3D heart is small, the size of a rabbit's heart," explains Prof. Dvir. "But larger human hearts require the same technology."

For the research, a biopsy of fatty tissue was taken from patients. The cellular and a-cellular materials of the tissue were then separated. While the cells were reprogrammed to become pluripotent stem cells, the extracellular matrix (ECM), a three-dimensional network of extracellular macromolecules such as collagen and glycoproteins, were processed into a personalized hydrogel that served as the printing "ink."

After being mixed with the hydrogel, the cells were efficiently differentiated to cardiac or endothelial cells to create patient-specific, immune-compatible cardiac patches with blood vessels and, subsequently, an entire heart.

According to Prof. Dvir, the use of "native" patient-specific materials is crucial to successfully engineering tissues and organs.

"The biocompatibility of engineered materials is crucial to eliminating the risk of implant rejection, which jeopardizes the success of such treatments," Prof. Dvir says. "Ideally, the biomaterial should possess the same biochemical, mechanical and topographical properties of the patient's own tissues. Here, we can report a simple approach to 3D-printed thick, vascularized and perfusable cardiac tissues that completely match the immunological, cellular, biochemical and anatomical properties of the patient."

The researchers are now planning on culturing the printed hearts in the lab and "teaching them to behave" like hearts, Prof. Dvir says. They then plan to transplant the 3D-printed heart in animal models.

"We need to develop the printed heart further," he concludes. "The cells need to form a pumping ability; they can currently contract, but we need them to work together. Our hope is that we will succeed and prove our method's efficacy and usefulness.

"Maybe, in ten years, there will be organ printers in the finest hospitals around the world, and these procedures will be conducted routinely."

Image caption: A 3D-printed, small-scaled human heart engineered from the patient's own materials and cells. Credit: Advanced Science. © 2019 The Authors.




Latest News

Joanna Naftali Named Associate Vice President, Midwest of AFTAU

Accomplished fundraiser has deep roots in educational, philanthropic, and arts sectors.

Blocking Inflammatory Pathway Key to Preventing Brain Metastasis from Melanoma

Tumor cells "hijack" their way to the brain through an inflammatory factor secreted by brain cells, say TAU researchers.

TAU and Technion Researchers Wrest Control of One of World's Most Secure PLCs

Rogue engineering station instigated "hostile intervention" of Siemens programmable logic controller that runs industrial processes.

Novel Immunotherapy May Prevent Brain Metastases

Injection of synthetic DNA material found to activate brain's immune cells and kill invading tumor cells, TAU researchers say.

TAU Scientists Develop Novel Nano-Vaccine for Melanoma

Injection of nanoparticle has proven effective in mouse models, researchers say.

Genetic Screen Identifies Genes That Protect Cells from Zika Virus

Genes found to safeguard against infection as well as resuscitate infected cells, TAU researchers say.

Jennifer Gross Named Chief Executive Officer of AFTAU

Accomplished executive brings extensive experience from Jewish philanthropy and the financial services industry.

Fat Cells Play Key Role in Dangerous Transformation of Melanoma

Fat cells allow melanoma cells to penetrate the dermis, causing fatal metastases in vital organs, TAU researchers say.

New Antibacterial Fillings from TAU May Combat Recurring Tooth Decay

Novel material may prevent one of the costliest and most prevalent bacterial diseases in the world.

First Proof-of-Concept Demonstrates Genetic Sex Selection in Mammals

Crossed transgenic mouse lines struck males without affecting females, TAU researchers say.

contentSecondary
c

© 2019 American Friends of Tel Aviv University
39 Broadway, Suite 1510 | New York, NY 10006 | 212.742.9070 | info@aftau.org
Privacy policy | Tel Aviv University